Anjana Pillai to Risk Assessment
This is a "connection" page, showing publications Anjana Pillai has written about Risk Assessment.
Connection Strength
0.203
-
Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Transplant Proc. 2010 Nov; 42(9):3647-51.
Score: 0.052
-
Survival Outcomes of Radiofrequency Ablation for Intrahepatic Cholangiocarcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database: Comparison with Radiotherapy and Resection. J Vasc Interv Radiol. 2025 Mar; 36(3):489-498.e3.
Score: 0.034
-
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):281-290.e4.
Score: 0.034
-
Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes. Liver Transpl. 2021 07; 27(7):1019-1031.
Score: 0.027
-
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2.
Score: 0.024
-
Liver Transplantation in the Obese Cirrhotic Patient. Transplantation. 2017 10; 101(10):2288-2296.
Score: 0.021
-
Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2008 May; 6(5):584-9.
Score: 0.011